Viralytics raises $4.7m to fund melanoma trial
Tuesday, 20 December, 2011
Viralytics has announced it has raised $4.7 million in a share purchase plan, which has raised the company’s cash reserves to over $8 million.
The fund raising was undertaken to coincide with the commencement of patient enrolment in the company’s US-based phase II melanoma trial.
The issue price of the shares was 30.84c and was based on the five day volume weighted price as of 14 December.
Viraltyics’ (ASX:VLA) share price dropped 5.5% to 34c by mid-afternoon, down from 36c at Monday’s close.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...